- Home
- RAND vs IGC Comparison
RAND vs IGC Comparison
Compare RAND & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAND | IGC |
|---|---|---|
| Founded | 1969 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 33.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RAND | IGC |
|---|---|---|
| Price | $15.75 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 3.4K | ★ 435.0K |
| Earning Date | 11-07-2025 | 11-17-2025 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,327,287.00 | $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.25 | $0.25 |
| 52 Week High | $31.89 | $0.50 |
Technical Indicators
Market Signals| Indicator | RAND | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 71.23 | 45.01 |
| Support Level | $13.95 | $0.28 |
| Resistance Level | $15.49 | $0.36 |
| Average True Range (ATR) | 0.48 | 0.02 |
| MACD | 0.23 | 0.00 |
| Stochastic Oscillator | 94.55 | 51.42 |
Price Performance
Historical ComparisonAbout RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.